Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients

Psychoneuroendocrinology

Volumn 32, Issue 5, 2007, Pages 464-469

  Watson, Stuart ^a   Gallagher, Peter ^a   Smith, Margaret S ^a   Young, Allan H ^a   Ferrier, I Nicol ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Argipressin; Bipolar disorder; Dex CRH test; Hypothalamic pituitary adrenal axis; Lithium; Major depressive disorder

Indexed keywords

ARGIPRESSIN; ATENOLOL; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CODYDRAMOL; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GABAPENTIN; HYDROCORTISONE; LAMOTRIGINE; LANSOPRAZOLE; LITHIUM; LORATADINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PROCYCLIDINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; THYROXINE; TRYPTOPHAN; VALPROIC ACID; WARFARIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; NEUROENDOCRINOLOGY; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; ARGININE VASOPRESSIN; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; FEMALE; HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LITHIUM COMPOUNDS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; REFERENCE VALUES; STIMULATION, CHEMICAL;

EID: 34248581144     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.02.010     Document Type: Article

References (36)

1. Aguilera G., Pham Q., and Rabadan-Diehl C. Regulation of pituitary vasopressin receptors during chronic stress: relationship to corticotroph responsiveness. J. Neuroendocrinol. 6 3 (1994) 299-304
2. Anai H., Ueta Y., Serino R., Nomura M., Kabashima N., Shibuya I., Takasugi M., Nakashima Y., and Yamashita H. Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat. Brain Res. 772 1-2 (1997) 161-166
3. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 14 2 (1993) 76-122
4. Baylis, P.H., 2003. Water and sodium homeostasis and their disorders. In: D.A. Warrell, C. T.M., F. J.D. (Eds.), Oxford Textbook of Medicine. Oxford, Oxford Medical Publications: 3116-3126.
5. Bendz H., and Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 21 6 (1999) 449-456
6. Bendz H., Sjodin I., and Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol. Dial. Transplant 11 3 (1996) 457-460
7. Boton R., Gaviria M., and Batlle D.C. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am. J. Kidney Dis. 10 5 (1987) 329-345
8. Bschor T., Adli M., Baethge C., Eichmannb U., Ising M., Uhr M., Modell S., Künzel H., Müller-Oerlinghausen B., and Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 27 3 (2002) 470-478
9. Bschor T., Baethge C., Adli M., Eichmann U., Ising M., Uhr M., Muller-Oerlinghausen B., and Bauer M. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress. Anxiety 17 1 (2003) 43-48
10. Daban C., Vieta E., Mackin P., and Young A.H. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 28 2 (2005) 469-480
11. Dinan T.G., O'Brien S., Lavelle E., and Scott L.V. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol. Med. 34 1 (2004) 169-172
12. Engelmann M., Wotjak C.T., Neumann I., Ludwig M., and Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 20 3 (1996) 341-358
13. Erkut Z.A., Pool C., and Swaab D.F. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J. Clin. Endocrinol. Metab. 83 6 (1998) 2066-2073
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version (1997), Biometrics Research, New York
15. Gispen-de Wied C.C., Westenberg H.G., Koppeschaar H.P., Thijssen J.H., and van Ree J.M. Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects. Eur. Neuropsychopharmacol. 2 4 (1992) 411-419
16. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., and Soubrie P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA 16 (2002) 16
17. Guirguis A.F., and Taylor H.C. Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature. Endocr. Pract. 6 4 (2000) 324-328
18. Karssen A.M., Meijer O.C., Berry A., Sanjuan Pinol R., and de Kloet E.R. Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology 146 12 (2005) 5587-5595
19. Keck M.E., Wigger A., Welt T., Muller M.B., Gesing A., Reul J.M.H.M., Holsboer F., Landgraf R., and Neumann I.D. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26 1 (2002) 94-105
20. Lehmann E.L. Nonparametrics. Statistical Methods Based on Ranks (1975), Holden-Day, San Francisco
21. Livingstone C., and Rampes H. Lithium: a review of its metabolic adverse effects. J. Psychopharmacol. 20 3 (2006) 347-355
22. Meynen G., Unmehopa U.A., van Heerikhuize J.J., Hofman M.A., Swaab D.F., and Hoogendijk W.J. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol. Psychiatr. 60 8 (2006) 892-895
23. Purba J.S., Hoogendijk W.J., Hofman M.A., and Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatr. 53 2 (1996) 137-143
24. Raadsheer F.C., Hoogendijk W.J., Stam F.C., Tilders F.J., and Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 4 (1994) 436-444
25. Rhodes M.E., O'Toole S.M., Czambel R.K., and Rubin R.T. Male-female differences in rat hypothalamic-pituitary-adrenal axis responses to nicotine stimulation. Brain Res. Bull. 54 6 (2001) 681-688
26. Ritchie J.C., Belkin B.M., Krishnan K.R., Nemeroff C.B., and Carroll B.J. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol. Psychiatr. 27 2 (1990) 159-173
27. Rooke P., and Baylis P.H. A new sensitive radioimmunoassay for plasma arginine vasopressin. J. Immunoassay 3 2 (1982) 115-131
28. Scott L.V., and Dinan T.G. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J. Affect. Disord. 72 2 (2002) 113-124
29. Serradeil-Le Gal C., Wagnon III J., Tonnerre B., Roux R., Garcia G., Griebel G., and Aulombard A. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 11 1 (2005) 53-68
30. SPSS. SPSS for Windows Version 9.0 (1998), Chicago, SPSS Inc
31. Stone K.A. Lithium-induced nephrogenic diabetes insipidus. J. Am. Board Fam. Pract. 12 1 (1999) 43-47
32. von Bardeleben U., Holsboer F., Stalla G., and Muller O. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37 17 (1985) 1613-1618
33. Walker R.J., Weggery S., Bedford J.J., McDonald F.J., Ellis G., and Leader J.P. Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int. 67 1 (2005) 291-294
34. Watson S., Gallagher P., Del-Estal D., Hearn A., Ferrier I.N., and Young A.H. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol. Med. 32 6 (2002) 1021-1028
35. Watson S., Gallagher P., Ritchie J.C., Ferrier I.N., and Young A.H. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br. J. Psychiatr. 184 (2004) 496-502
36. Watson S., Gallagher P., Ferrier I.N., and Young A.H. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J. Psychiatr. Res. 40 4 (2006) 353-359